December 2021 Foundation eNews
Nearly $1 Million in ALS Grants Awarded for 2022! The Les Turner ALS Foundation is excited to announce nearly $1 million to be funded in 2022 for new research grants and clinic and endowment support to the Les Turner ALS …
ALS News Today: New Directions in Research, Care Focus of Les Turner ALS Symposium
By Marta Figueiredo PhD | November 18, 2021 Recent findings and ongoing efforts to more fully understand the underlying molecular mechanisms of amyotrophic lateral sclerosis (ALS), and to identify new and better ways of helping patients were discussed at the 11th Annual Les Turner Symposium …
Faces of ALS: Air Force Veteran Lori Hoover
Lori’s Story: Aim High…Fly-Fight-Win! Every November on Veterans Day, we honor and remember the veterans who served our country in the Armed Forces. Due to the strong connection between military service and ALS, the Foundation also remembers and honors those …
November 2021 Foundation eNews
Amylyx Pharmaceuticals Has Submitted a New Drug Application to the FDA for AMX0035 to Treat ALS Amylyx Pharmaceuticals today announced it has submitted a New Drug Application (NDA) to the FDA for AMX0035 for the treatment of ALS. This New …
November 2021 Events eNews
Special Feature on Support Groups As November is National Family Caregivers Month, this edition of ALS Event News focuses on support groups for people living with ALS and their families. The Les Turner ALS Foundation has long offered comforting …
Biogen Briefing Notes – Scientific Advisory Council (SAC)
The following note is being passed along from the Board of Directors of the International Alliance of ALS/MND Associations… The Board of Directors of the International Alliance of ALS/MND Associations is pleased to provide information for Member Associations in the …
October 2021 Foundation eNews
FOUNDATION NEWS AMX0035 May Slow ALS Progression and Extend Life On September 15, Amylyx Pharmaceuticals announced its intention to submit a New Drug Application to the FDA for AMX0035 for the treatment of ALS. If the New Drug Application is …
AMX0035 May Slow ALS Progression and Extend Life
On September 15, Amylyx Pharmaceuticals announced its intention to submit a New Drug Application to the FDA for AMX0035 for the treatment of ALS. If the New Drug Application is successful, AMX0035 would be only the third drug approved by …
September 2021 Events eNews
There’s Still Time to Join the ALS Community at the ALS Walk for Life The forecast for Saturday’s ALS Walk for Life is abundant sunshine with widespread warmth. And the weather is expected to be nice too! Let’s thank …